Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.58 |
| ▸ | FPR2 | P25090 | 1/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 2/20 | 0.55 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493021 | 0.91 | CNR1 (0.60) | CNR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492798 | 0.89 | PSEN1 (0.72) | CNR1FPR2PSEN1PSEN2APH1B | |
| SCHEMBL1492664 | 0.88 | CNR1 (0.62) | CNR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492756 | 0.87 | FPR2 (0.61) | CNR1FPR2PSEN1PSEN2APH1B | |
| SCHEMBL1492683 | 0.86 | CNR1 (0.60) | CNR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492885 | 0.85 | PORCN (0.71) | CNR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492661 | 0.84 | WNT3A (0.57) | CNR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492651 | 0.83 | PSEN1 (0.69) | CNR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492868 | 0.83 | WNT3A (0.53) | CNR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492949 | 0.82 | WNT3A (0.50) | CNR1FPR2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083794-A | Urea compounds as gamma secretase modulators | AMGEN INC | 2011-06-01 | — | — | CN | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | claimed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | CNR1 2240/4885FPR2 4160/4885PSEN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.